Used in targeted cancer therapy, particularly for triple-negative breast cancer and other solid tumors expressing TROP2. Delivers cytotoxic agents directly to tumor cells by binding to TROP2 antigen, minimizing damage to healthy tissues. Serves as a reference standard in development and quality control of biosimilars and immunoassays. Supports research in antibody-drug conjugates (ADCs) for improved efficacy and safety profiles.